background
time
identif
respiratori
viru
infect
essenti
mitig
inappropri
antibiot
use
implement
appropri
treatment
andor
infect
control
procedur
multiplex
pcr
assay
becom
standard
mani
virolog
laboratori
object
compar
seeplex
test
record
two
newer
gener
multiplex
assay
anyplex
ii
xtag
respiratori
viru
panel
studi
design
two
hundr
three
retrospect
prospect
respiratori
sampl
test
three
assay
sampl
deem
posit
test
posit
viru
least
two
three
respect
assay
neg
sampl
also
test
neg
least
two
three
assay
inconclus
sampl
show
band
signal
intens
previous
test
xtag
result
conclus
overal
sensit
specif
three
assay
similar
respect
given
assay
identifi
multipl
differ
virus
target
report
one
assay
alway
agre
target
anoth
assay
partial
discord
rate
posit
neg
sampl
respect
higher
expect
partial
discord
rate
may
due
primer
chemistri
differ
amongst
three
multiplex
assay
respiratori
viral
infect
signific
caus
morbid
mortal
global
esposito
et
al
huijsken
et
al
earli
identif
respiratori
pathogen
permit
rapid
implement
appropri
infect
control
precaut
decreas
antibiot
use
appropri
initi
antivir
therapi
barenfang
et
al
heinonen
et
al
tradit
laboratori
method
viral
cultur
direct
fluorescentantibodi
test
time
consum
lack
sensit
longer
method
choic
gharabaghi
et
al
et
al
current
molecular
method
standard
employ
virolog
laboratori
multiplex
assay
enabl
detect
sever
viral
target
permit
simultan
identif
coinfect
patient
specimen
esper
et
al
current
sever
multiplex
assay
avail
commerci
three
health
canada
approv
assay
includ
seeplex
ace
detect
kit
seegen
south
korea
anyplex
ii
seegen
south
korea
xtag
respiratori
viral
panel
xtag
luminex
unit
state
multiplex
assay
base
dual
prime
oligonucleotid
dpo
technolog
bruijnesteijn
van
coppenraet
et
al
list
fifteen
detect
virus
includ
influenza
viru
inf
influenza
b
viru
inf
b
respiratori
syncyti
virus
b
rsva
rsvb
adenoviru
adv
human
metapneumoviru
hmpv
coronaviru
cov
parainfluenza
virus
piv
rhinoviru
rhv
c
enteroviru
ev
bocavirus
bov
base
tag
oligo
cleavag
extens
technolog
make
possibl
detect
multipl
pathogen
singl
fluoresc
channel
use
real
time
pcr
kim
et
al
detect
total
virus
includ
serotyp
viru
viral
panel
ident
viral
panel
addit
detect
cov
cov
virus
luminex
xtag
system
liquidbeadsuspensionarray
base
multiplex
pcr
jokela
et
al
bocavirus
previous
includ
viral
panel
xtag
howev
version
analyz
studi
viral
target
part
test
panel
thu
studi
aim
compar
diagnost
perform
xtag
assay
test
assay
record
patient
respiratori
specimen
includ
nasopharyng
swab
np
bronchoalveolar
lavag
bal
fluid
sampl
submit
test
collect
novemb
june
np
sampl
collect
use
flock
swab
starwab
multitran
collect
transport
system
total
sampl
collect
sampl
retrospect
prospect
retrospect
sampl
sampl
aliquot
store
undergo
one
freezethaw
cycl
retrospect
sampl
test
simultan
anyplex
ii
xtag
prospect
sampl
test
receiv
laboratori
simultan
test
three
assay
patient
demograph
studi
follow
femal
patient
rang
year
old
male
patient
rang
year
old
mean
age
femal
male
patient
studi
year
old
respect
nucleic
acid
extract
assay
perform
magnapur
compact
roch
switzerland
initi
input
volum
seegen
extract
lysi
buffer
patient
sampl
final
elut
volum
sampl
luminex
magpix
assay
initi
input
volum
lysi
buffer
patient
sampl
final
elut
volum
bacteriophag
ad
intern
control
prior
extract
luminex
magpix
seegen
assay
per
manufactur
instruct
seegen
intern
control
specif
primer
ad
follow
extract
accord
manufactur
instruct
sampl
test
use
seegen
seeplex
one
step
ace
detect
kit
sampl
simultan
amplifi
three
separ
reaction
correspond
primer
set
specifi
b
c
final
volum
pcr
reaction
mixtur
contain
onestep
rtpcr
master
mix
sampl
eluat
master
mix
composit
per
manufactur
instruct
thermocycl
condit
use
seeamp
thermocycl
reaction
mixtur
vortex
prior
thermocycl
allow
thorough
reaction
mix
amplifi
pcr
product
analyz
agaros
gel
electrophoresi
use
calip
gel
base
detect
platform
life
scienc
unit
state
follow
analysi
seegen
viewer
softwar
assign
posit
neg
result
viru
present
sampl
test
viral
panel
sampl
test
use
seegen
detect
kit
revers
transcript
perform
follow
cdna
synthesi
seeamp
thermocycl
use
manufactur
specif
pcr
conduct
final
volum
reaction
analyz
realtim
pcr
system
biorad
use
manufactur
instruct
catcher
melt
temperatur
analysi
cmta
achiev
cool
sampl
heat
mixtur
heat
period
fluoresc
f
temperatur
measur
continu
curv
neg
deriv
fluoresc
temperatur
versu
temperatur
dfdt
versu
gener
determin
sampl
melt
point
melt
point
interpret
use
seegen
viewer
softwar
either
viru
subtyp
rv
limit
detect
copi
viru
type
report
manufactur
manufactur
product
insert
indic
strain
variat
caus
sensit
enteroviru
rhinoviru
vari
fold
revers
transcript
cdna
amplif
conduct
luminex
magpix
per
manufactur
instruct
use
eppendorf
thermocycl
ramp
speed
follow
revers
transcript
cdna
amplif
bead
hybrid
hybrid
plate
transfer
luminex
magpix
detect
well
analyz
bead
hybrid
use
tda
rvp
fast
softwar
cutoff
threshold
viru
determin
base
previous
determin
threshold
manufactur
sampl
consid
posit
viru
serotyp
threshold
met
exceed
sampl
consid
posit
sampl
test
posit
viru
least
two
three
assay
sampl
deem
neg
test
neg
least
two
three
assay
inconclus
result
previous
defin
posit
specimen
band
signal
intens
specimen
viru
virus
identifi
concord
three
assay
conflict
result
classifi
base
discord
viru
ident
analyz
accordingli
agreement
sensit
specif
calcul
assay
distribut
virus
detect
shown
tabl
use
definit
posit
neg
result
agreement
two
three
assay
total
posit
specimen
identifi
specimen
coinfect
one
type
viru
sampl
dual
tripl
coinfect
respect
eightysix
posit
sampl
show
complet
agreement
among
three
assay
seventyf
posit
specimen
partial
discord
result
viru
identifi
two
three
assay
sampl
singl
discord
sampl
two
discord
present
one
sampl
three
four
discord
respect
tabl
provid
repres
list
specimen
respect
result
assay
noteworthi
assay
identifi
one
common
viru
one
assay
also
identifi
differ
second
third
viru
result
patient
coinfect
profil
result
report
partial
discord
one
influenza
influenza
b
posit
sampl
respect
discord
influenza
detect
least
one
assay
rsv
b
sampl
respect
discord
viru
detect
one
assay
total
sampl
classifi
neg
virus
least
two
assay
neg
result
tabl
outlin
sixteen
neg
sampl
display
discord
result
sampl
singl
doubl
tripl
discord
respect
twenti
twentyseven
sampl
inconclus
viru
test
found
posit
test
multiplex
assay
weak
signal
found
virustyp
among
twentyseven
sampl
breakdown
inconclus
result
shown
tabl
respect
xtag
assay
result
overal
sensit
specif
three
assay
xtag
multipl
viru
type
commonli
detect
xtag
compar
two
assay
bocaviru
signal
common
xtag
system
either
rv
panel
vs
one
rsv
posit
sampl
test
xtag
system
display
signal
rsv
influenza
b
rhinoenteroviru
metapneumoviru
bocaviru
tabl
includ
represent
rsv
influenza
b
test
assay
sensit
specif
calcul
perform
three
assay
evalu
equival
small
number
viru
type
expect
skew
sensit
calcul
exampl
sensit
xtag
influenza
b
report
assay
detect
posit
sampl
three
assay
overal
sensit
similar
respect
sensit
three
platform
gener
less
report
kim
et
al
specif
ident
kim
et
al
coinfect
rate
present
studi
similar
describ
kim
et
al
kim
et
al
interest
given
geograph
tempor
differ
two
studi
studi
design
larg
retrospect
major
sampl
factor
may
bias
result
favor
earlier
gener
assay
one
may
expect
perform
less
effect
compar
studi
addit
effect
freezethaw
cycl
sampl
done
xtag
viru
detect
accuraci
analyz
limit
studi
sampl
input
among
three
assay
also
vari
input
xtag
respect
issu
identifi
assay
use
intern
control
base
result
obtain
studi
alter
sampl
input
affect
sensit
assay
howev
lower
sampl
input
may
benefici
patient
sampl
volum
limit
respect
xtag
assay
may
favor
discord
rate
amongst
posit
sampl
high
may
reflect
preferenti
chemistri
primer
set
virustyp
match
one
assay
versu
anoth
upon
closer
inspect
data
one
see
variat
differ
assay
respect
certain
viru
type
sensit
limit
evalu
investig
differ
sequenc
monoplex
pcr
test
conduct
discord
sampl
addit
convent
method
cell
cultur
direct
fluoresc
antibodi
test
perform
sensit
detect
influenza
three
system
gener
good
equal
xtag
less
poor
perform
xtag
influenza
b
alreadi
address
discord
result
amongst
influenza
rsv
low
sensit
rhinoviru
enteroviru
poorer
two
assay
find
similar
kim
et
al
report
previous
kim
et
al
assum
sampl
individu
clinic
symptom
howev
chart
review
done
confirm
case
given
high
sensit
multiplex
assay
probabl
asymptomat
convalesc
individu
may
shed
viru
genom
consider
period
time
would
especi
true
adenoviru
infect
patient
may
account
level
coinfect
seen
three
aforement
assay
would
accept
use
laboratori
detect
respiratori
virus
ultim
eas
use
time
complet
cost
consum
materi
dictat
test
methodolog
prefer
follow
studi
replac
hous
inconclus
result
howev
also
mani
commerci
multiplex
assay
market
exampl
includ
ftd
respiratori
fasttrack
diagnost
ep
respiratori
ausdiagnost
filmarray
respiratori
panel
biofir
diagnosticsbiomerieux
verigen
rv
test
nanospher
prodess
respiratori
assay
hologicgenprob
invitro
diagnost
ivd
indic
variou
licens
bodi
ie
fda
health
canada
ce
choos
assay
may
influenc
jurisdict
approv
ivd
conclus
implement
laboratori
inconclus
result
previous
obtain
resolv
next
gener
platform
platform
also
improv
workflow
compar
gelbas
detect
rtpcr
deem
easier
interpret
